KR101120857B1 - 5원의 헤테로사이클-기재 p38 키나제 억제제 - Google Patents
5원의 헤테로사이클-기재 p38 키나제 억제제 Download PDFInfo
- Publication number
- KR101120857B1 KR101120857B1 KR1020057024679A KR20057024679A KR101120857B1 KR 101120857 B1 KR101120857 B1 KR 101120857B1 KR 1020057024679 A KR1020057024679 A KR 1020057024679A KR 20057024679 A KR20057024679 A KR 20057024679A KR 101120857 B1 KR101120857 B1 KR 101120857B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- amino
- cyclopropyl
- benzoyl
- benzamide
- Prior art date
Links
- 0 C1CNC=*C1 Chemical compound C1CNC=*C1 0.000 description 9
- MRDFLILXEIMYNW-UHFFFAOYSA-N Cc(ccc(C(NC1CC1)=O)c1)c1-[n](c(N)c1C(c2ccccc2)=O)nc1S(C)(=O)=O Chemical compound Cc(ccc(C(NC1CC1)=O)c1)c1-[n](c(N)c1C(c2ccccc2)=O)nc1S(C)(=O)=O MRDFLILXEIMYNW-UHFFFAOYSA-N 0.000 description 2
- SDMIRTQDZFHAOX-UHFFFAOYSA-N Cc(ccc(C(NC1CC1)=O)c1)c1-[n]1ncc(C(c2ccccn2)=O)c1N Chemical compound Cc(ccc(C(NC1CC1)=O)c1)c1-[n]1ncc(C(c2ccccn2)=O)c1N SDMIRTQDZFHAOX-UHFFFAOYSA-N 0.000 description 2
- WMXQCPFNDCTFOI-XVNBXDOJSA-N Bc1cccc(C(c2c(N)[n](/C=C/CC)cn2)=O)c1 Chemical compound Bc1cccc(C(c2c(N)[n](/C=C/CC)cn2)=O)c1 WMXQCPFNDCTFOI-XVNBXDOJSA-N 0.000 description 1
- IRNFUDNTQVEZNF-ONEGZZNKSA-N CC/C=C/[n]1c(N)c(C#N)nc1 Chemical compound CC/C=C/[n]1c(N)c(C#N)nc1 IRNFUDNTQVEZNF-ONEGZZNKSA-N 0.000 description 1
- XWGSTRFFSXATEC-UHFFFAOYSA-N Cc(c(-[n]1c(N)c(C(c2cccc(-c3ncccn3)c2)=O)nc1)c1)ccc1C(NC1CC1)=O Chemical compound Cc(c(-[n]1c(N)c(C(c2cccc(-c3ncccn3)c2)=O)nc1)c1)ccc1C(NC1CC1)=O XWGSTRFFSXATEC-UHFFFAOYSA-N 0.000 description 1
- GWHQURVCNJLILJ-UHFFFAOYSA-N Cc(c(-[n]1c(N)c(C(c2cccc(C(NC3CC3)=O)c2)=O)nc1)c1)ccc1C(NC1CC1)=O Chemical compound Cc(c(-[n]1c(N)c(C(c2cccc(C(NC3CC3)=O)c2)=O)nc1)c1)ccc1C(NC1CC1)=O GWHQURVCNJLILJ-UHFFFAOYSA-N 0.000 description 1
- KTQPECIQEHQUBN-UHFFFAOYSA-N Cc(c(-[n]1c(N)c(C(c2cccc(C(NC3CCCC3)=O)c2)=O)nc1)c1)ccc1C(NC1CC1)=O Chemical compound Cc(c(-[n]1c(N)c(C(c2cccc(C(NC3CCCC3)=O)c2)=O)nc1)c1)ccc1C(NC1CC1)=O KTQPECIQEHQUBN-UHFFFAOYSA-N 0.000 description 1
- HDERKBWRNZMYBW-UHFFFAOYSA-N Cc(c(-[n]1ncc(C(c(cccc2)c2OC)=O)c1N)c1)ccc1C(NC1CC1)=O Chemical compound Cc(c(-[n]1ncc(C(c(cccc2)c2OC)=O)c1N)c1)ccc1C(NC1CC1)=O HDERKBWRNZMYBW-UHFFFAOYSA-N 0.000 description 1
- ZWWMSWCLDWRNLU-UHFFFAOYSA-N Cc(ccc(C(NC1CC1)=O)c1)c1-[n](c(N)c1C(c2ccccc2)=O)nc1SC Chemical compound Cc(ccc(C(NC1CC1)=O)c1)c1-[n](c(N)c1C(c2ccccc2)=O)nc1SC ZWWMSWCLDWRNLU-UHFFFAOYSA-N 0.000 description 1
- SFQHBOLXISPDBA-UHFFFAOYSA-N Cc(ccc(C(NC1CC1)=O)c1)c1-[n]1c(N)c(C(c2cc(-c3cnccn3)ccc2)=O)nc1 Chemical compound Cc(ccc(C(NC1CC1)=O)c1)c1-[n]1c(N)c(C(c2cc(-c3cnccn3)ccc2)=O)nc1 SFQHBOLXISPDBA-UHFFFAOYSA-N 0.000 description 1
- ACDYVZWXLZVGKZ-UHFFFAOYSA-N Cc(ccc(C(NC1CC1)=O)c1)c1-[n]1ncc(C(c2cc(C=O)ccc2)=O)c1N Chemical compound Cc(ccc(C(NC1CC1)=O)c1)c1-[n]1ncc(C(c2cc(C=O)ccc2)=O)c1N ACDYVZWXLZVGKZ-UHFFFAOYSA-N 0.000 description 1
- LDSWVDXHAVPQKP-UHFFFAOYSA-N Cc(ccc(C(NC1CC1)=O)c1)c1N(C1N)N=CC1C#N Chemical compound Cc(ccc(C(NC1CC1)=O)c1)c1N(C1N)N=CC1C#N LDSWVDXHAVPQKP-UHFFFAOYSA-N 0.000 description 1
- GPPJCACAUPJXSP-VLAXSBJUSA-O Cc(ccc(C(NC1CC1)=O)c1)c1N/C(/N)=C(\C=[NH2+])/C(c1cc(C2OCCO2)ccc1)=O Chemical compound Cc(ccc(C(NC1CC1)=O)c1)c1N/C(/N)=C(\C=[NH2+])/C(c1cc(C2OCCO2)ccc1)=O GPPJCACAUPJXSP-VLAXSBJUSA-O 0.000 description 1
- WBBNMFQHIHEKPO-UHFFFAOYSA-N Cc1cc(C(c2c(N)[n](-c3cc(C(NC4CC4)=O)ccc3C)nc2)=O)ccc1 Chemical compound Cc1cc(C(c2c(N)[n](-c3cc(C(NC4CC4)=O)ccc3C)nc2)=O)ccc1 WBBNMFQHIHEKPO-UHFFFAOYSA-N 0.000 description 1
- FVBVNEOHHSOQGF-UHFFFAOYSA-N Cc1ccccc1C(c1c(N)[n](-c2c(C)ccc(C(NC3CC3)=O)c2)nc1)=O Chemical compound Cc1ccccc1C(c1c(N)[n](-c2c(C)ccc(C(NC3CC3)=O)c2)nc1)=O FVBVNEOHHSOQGF-UHFFFAOYSA-N 0.000 description 1
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N Cc1nccnc1 Chemical compound Cc1nccnc1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 1
- CCZWSTFVHJPCEM-UHFFFAOYSA-N Ic1ncccc1 Chemical compound Ic1ncccc1 CCZWSTFVHJPCEM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Description
Claims (129)
- 하기 화학식의 화합물 또는 그의 제약학상 허용되는 염.식 중에서,R1은 수소이고;R2는 수소, 알킬, 알킬티오, 알킬술포닐, 치환될 수 있는 알콕시 (여기서 2개 이하의 치환기는 -OR (R = 알킬) 및 페닐에서 선택됨), 3-클로로벤질아미노카르보닐메톡시 또는 치환될 수 있는 헤테로시클릴옥시 (여기서 헤테로시클릴은 3 내지 8개의 고리 원자의 시클릭 비방향족 라디칼을 의미하고, 여기서 1개 또는 2개의 고리 원자는 N이고, 다른 고리 원자는 C이고, 2개 이하의 치환기는 -COOR (R은 알킬)에서 선택됨)이고;G는 페닐, 피리딜, 시클로헥실, 시클로펜틸 또는 벤질이고, R3 및 R4로 치환되고, 단 피리딜 고리는 탄소 고리 원자를 통해서 카르보닐기에 결합되거나, 또는 G는 OR83 또는 NR80R81이고;B는 페닐이고;C는 피라졸 또는 이미다졸 고리이고;D은 1 내지 3개의 N 헤테로원자를 함유하고, 다른 고리 원자는 C 또는 -CO(O)NR80xR81x인 5 내지 10개의 고리 원자의 1가 모노시클릭 라디칼을 의미하는 헤테로아릴이며 (여기서, R80x 및 R81x는 수소, 알콕시, 또는 1개의 고리 및 3 내지 7개의 탄소 원자를 함유하는 시클로알킬임),각각의 R80 및 R81은 독립적으로 수소, 알킬 또는 시클로알킬 (1 내지 3개의 고리를 갖고, 고리 당 3 내지 7개의 탄소 원자를 가지며, 불포화 C3-C7 카르보시클릭 고리와 추가로 융합될 수 있는 포화 비방향족 시클릭 탄화수소 시스템이고, 치환되지 않거나 알킬, 1-에티닐시클로헥실, 메톡시벤질, 벤질, 3-클로로벤질, 2,4-디클로로벤질, 시클로헥실메틸, 3,4-디클로로벤질, 3-트리플루오로메틸벤질, 플루오로벤질, N-에틸-2-피리디닐메틸, 메틸벤질, 피리딜메틸, 모르폴리닐에틸, 1-시클로헥실에틸, 1-페닐에틸 또는 2-피리디닐에틸에서 독립적으로 선택되는 1 또는 2개의 치환기로 치환됨)이고;R83는 수소, 알킬 또는 3 내지 7개의 탄소 원자를 갖는 포화 비방향족 탄화수소 고리인 시클로알킬이고;R3은(a) 아미노, 알킬아미노 또는 디알킬아미노;(b) 치환될 수 있는 헤테로시클릴 (1개 또는 2개의 고리 원자가 N 및 O에서 선택되는 헤테로원자이고, 다른 고리 원자가 C이고, 치환기가 1개 또는 2개의 독립적으로 선택되는 알킬 치환기일 수 있는, 3 내지 8개의 고리 원자의 시클릭 비방향족 라디칼임);(c) 치환될 수 있는 헤테로아릴 (1 내지 3개의 고리 원자가 N 및 O에서 선택되고, 다른 고리 원자는 C이며, 치환기가 1개 또는 2개의 독립적으로 선택되는 알킬 치환기일 수 있는, 5 내지 10개의 고리 원자의 모노시클릭 라디칼임);(d) 치환될 수 있는 헤테로시클릴알킬 (여기서, 헤테로시클릴이 1개 또는 2개의 고리 원자가 N 및 O에서 선택되는 헤테로원자이고, 다른 고리 원자가 C이며, 치환기가 2개의 독립적으로 선택되는 알킬 치환기일 수 있는, 3 내지 8개의 고리 원자의 시클릭 비방향족 라디칼임);(e) 알킬로 치환될 수 있는 모르폴리노-, 피페리디노-, 피롤리디노- 또는 S,S-디옥소티오모르폴리노-알콕시;(f) -Y-(알킬렌)-R9 (여기서 Y는 -O-이고; R9는 1 내지 3개의 고리 헤테로원자가 N 및 O에서 선택되고, 다른 고리 원자가 C, -COOH, -COR10 또는 -CONR12R13이며, R10은 알킬이고, R12 및 R13 은 서로 독립적으로 수소 또는 알킬인, 5 내지 10개의 고리 원자의 모노시클릭 방향족 라디칼인 헤테로아릴임);(g) -CONR25R26 (여기서 R25 및 R26은 독립적으로 수소 또는 알킬을 나타내거나, 또는 R25 및 R26은 이들이 결합된 질소와 함께 피롤리디노, 피페리디노, 모르폴리노, 피페라지노 또는 S,S-디옥소티오모르폴리노를 형성함);(h) 수소;(i) 할로;(j) 시아노;(k) 히드록시;(l) 페닐, -CONR'R" (여기서, R' 및 R"는 함께 피롤리디노 또는 모르폴리노를 형성함), NRR' (여기서 R 및 R'는 독립적으로 수소 및 알킬에서 선택됨), 및 -OR (여기서, R은 수소 또는 알킬임)에서 선택되는 1개 또는 2개의 치환기로 치환될 수 있는 알콕시;(m) C(L)R40 (여기서 L은 O이고, R40은 수소, OR55 또는 NR57R58이고; 여기서 R55는 수소 또는 알킬, 알케닐, 알키닐, 아릴, 헤테로아릴, 헤테로아릴륨, 시클로알킬 또는 헤테로시클릴이고; R57 및 R58은 각각 독립적으로 수소 또는 1개의 고리 및 3 내지 7개의 탄소 원자를 함유하는 시클로알킬임),(n) 알킬 또는 히드록시알킬;(o) 2-(4-메틸피페라진-1-일)-2-엑소-에톡시, 2-(3-아미노-피롤리딘-1-일)-2-옥소-에톡시, 2-(3-메틸아미노-피롤리딘-1-일)-2-옥소-에톡시, [(1H-벤조이미다졸-2-일메틸)-카르바모일]-메톡시, [2-(2-벤질옥시-5-클로로-페닐)-에틸카르바모일]-메톡시, [2-(5-클로로-2-히드록시-페닐)-에틸카르바모일]-메톡시 또는 4-피페라지닐메틸;(p) 시클로프로폭시;(q) 메틸티오; 및(r) 메틸술포닐로 이루어진 군에서 선택되고,R4는(a) 수소;(b) 할로;(c) 알킬;(d) 알콕시; 및(e) 히드록시로 이루어진 군에서 선택되거나;또는 R3 및 R4가 고리 상에서 인접하는 원자를 치환하여 함께 알킬렌디옥시를 형성하고;R5는 수소이고;R6은(a) 수소; 및(b) 알킬로 이루어진 군에서 선택되거나;3-(5-아미노-4-{3-[(3-클로로-벤질아미노)-메틸]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드, 3-[5-아미노-4-(3-{[2-(3-클로로-페닐)-에틸아미노]-메틸}-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드, 3-(5-아미노-4-{3-[4-(3-클로로-페닐)-피페라진-1-일메틸]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드, 3-[5-아미노-4-(3-{[2-(2-벤질옥시-5-클로로-페닐)-에틸아미노]-메틸}-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드, 3-(5-아미노-4-{3-[(2-모르폴린-4-일-에틸아미노)-메틸]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드, 3-(5-아미노-4-{3-[(3-모르폴린-4-일-프로필아미노)-메틸]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드, 3-[5-아미노-4-(3-비닐옥시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드, 5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 페닐아미드, 3-{5-아미노-4-[3-(4H-[1,2,4]트리아졸-3-일)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드 또는 3-(5-아미노-4-{3-[2-(3,5-디메틸-피페라진-1-일)-2-옥소-에톡시]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드이며,여기서 알킬 및 알콕시는 1 내지 6개의 탄소원자의 선형 포화 1가 탄화수소 라디칼 또는 3 내지 6개의 탄소원자의 분지된 포화 1가 탄화수소이다.
- 제1항에 있어서, G가 OR83 또는 NR80R81인 화합물.
- 제1항에 있어서, G가 페닐, 피리딜, 시클로헥실, 시클로펜틸 또는 벤질이며, R3 및 R4로 치환된 것인 화합물.
- 제1항에 있어서, G가 페닐이며, R3 및 R4로 치환된 것인 화합물.
- 제1항에 있어서, C가 이미다졸 고리인 화합물.
- 제1항에 있어서, C가 피라졸 고리인 화합물.
- 제1항에 있어서, R1이 수소인 화합물.
- 제1항에 있어서, R2가 수소, 메틸, n-프로필 또는 3-클로로벤질아미노카르보닐메톡시인 화합물.
- 제7항에 있어서, A가 페닐 고리인 화합물.
- 제7항에 있어서, B가 페닐 고리인 화합물.
- 제1항에 있어서, R3이 시아노인 화합물.
- 제1항에 있어서, R3이 수소, 독립적으로 1개 또는 2개의 C1-6 알킬 치환기로 치환될 수 있는 디옥솔라닐, 피리미디닐, 피리딜, 피라지닐, 시아노, 옥사디아졸릴, 트리아졸릴, 메틸티오 또는 메탄술포닐인 화합물.
- 제1항에 있어서, R3이 N-모르폴리닐메틸, 히드록시메틸, N-(2-(3-클로로페닐)-1-에틸)아미노메틸, N-(2-모르폴리닐-1-에틸)아미노메틸, (3-클로로-벤질아미노)-메틸, 4-(3-클로로-페닐)-피페라진-1-일메틸, [2-(2-벤질옥시-5-클로로-페닐)-에틸아미노]-메틸, (3-모르폴린-4-일-프로필아미노)-메틸, 카르바모일메톡시, 2-(4-메틸-피페라진-1-일)-2-옥소-에톡시, 2-옥소-2-피페라진-1-일-에톡시, 2-(3-아미노-피롤리딘-1-일)-2-옥소-에톡시, 2-(3-메틸아미노-피롤리딘-1-일)-2-옥소-에톡시, 2-(3,5-디메틸-피페라진-1-일)-2-옥소-에톡시, 2-모르폴린-4-일-2-옥소-에톡시, [(1H-벤조이미다졸-2-일메틸)-카르바모일]-메톡시, [2-(2-벤질옥시-5-클로로-페닐)-에틸카르바모일]-메톡시, [2-(5-클로로-2-히드록시-페닐)-에틸카르바모일]-메톡시 또는 4-피페리지닐메틸인 화합물.
- 제7항에 있어서, R4가 수소인 화합물.
- 제7항에 있어서, R5가 메틸인 화합물.
- 제7항에 있어서, R6이 수소인 화합물.
- 제1항에 있어서, R1 및 R2가 수소이고, B가 페닐인 화합물.
- 제1항에 있어서, R3이 3-위치에 존재하는 것인 화합물.
- 제1항에 있어서,3-[5-아미노-4-(3-요오도-벤조일)-피라졸-1-일]-N-메톡시-4-메틸-벤즈아미드;3-(5-아미노-4-벤조일-피라졸-1-일)-N-메톡시-4-메틸-벤즈아미드;3-(5-아미노-4-벤조일-피라졸-1-일)-4-메틸-벤조산;3-(5-아미노-4-벤조일-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-요오도-벤조일)-피라졸-1-일]-4-메틸-벤조산;3-[5-아미노-4-(3-요오도-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;{5-아미노-1-[2-메틸-5-(4H-[1,2,4]트리아졸-3-일)-페닐]-1H-피라졸-4-일}-페닐-메타논;3-[5-아미노-4-(3-[1,3]디옥솔란-2-일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-포르밀-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-히드록시메틸-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(4-메틸-피페라진-1-일메틸)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-모르폴린-4-일메틸-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(2-모르폴린-4-일-에톡시)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-벤질옥시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-히드록시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-메틸-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드; 및3-(5-아미노-4-벤조일-이미다졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드로부터 선택되는 화합물.
- 제1항에 있어서, 3-(5-아미노-4-벤조일-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드 또는 그의 제약학상 허용되는 염인 화합물.
- 제1항에 있어서,3-(5-아미노-4-벤조일-이미다졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-시클로헥산카르보닐-이미다졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-시클로펜탄카르보닐-이미다졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-페닐아세틸-이미다졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-이소프로필카르바모일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(2-디메틸아미노-에틸카르바모일)-벤조일]-이미다졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-에틸카르바모일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-메틸카르바모일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-시클로프로필카르바모일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-시클로펜틸카르바모일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(모르폴린-4-카르보닐)-벤조일]-이미다졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(시클로프로필메틸-카르바모일)-벤조일]-이미다졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(테트라히드로-피란-4-카르보닐)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-벤조일-3-메톡시-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-벤조일-3-에톡시-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-벤조일-3-(2-메톡시-에톡시)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-벤조일-3-(2-벤질옥시-에톡시)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;4-[5-아미노-4-벤조일-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-3-일옥시]-피페리딘-1-카르복실산 tert-부틸 에스테르;3-[5-아미노-4-벤조일-3-(피페리딘-4-일옥시)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-벤조일-3-메틸술파닐-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-벤조일-3-메탄술포닐-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-3-메틸술파닐-1H-피라졸-4-카르복실산 아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-3-메탄술포닐-1H-피라졸-4-카르복실산 아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-3-메틸술파닐-1H-피라졸-4-카르복실산 에틸 에스테르;3-[5-아미노-4-(3-클로로벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-메틸-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(2-메틸벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(2-메톡시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-클로로벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(2-클로로벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-메톡시-벤조일)-피라졸-1-일]-4,N-디메틸-벤즈아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 에틸 에스테르;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-3-메틸-1H-피라졸-4-카르복실산 에틸 에스테르;5-아미노-3-[(3-클로로-벤질카르바모일)-메톡시]-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 에틸 에스테르;3-(5-아미노-4-벤조일-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(3-[1,3,4]옥사디아졸-2-일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-{5-아미노-4-[3-(5-메틸-[1,3,4]옥사디아졸-2-일)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(피롤리딘-1-카르보닐)-벤조일]-이미다졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-시클로프로필카르바모일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-카르바모일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-이소프로필카르바모일벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(4-메틸카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-시클로프로필카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(피페라진-1-카르보닐)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-디메틸카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(시클로프로필메틸-카르바모일)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-에틸카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-메틸카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-시클로펜틸카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-이소프로필카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-시클로프로필카르바모일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-{3-[(3-클로로-벤질아미노)-메틸]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-{[2-(3-클로로-페닐)-에틸아미노]-메틸}-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-{3-[4-(3-클로로-페닐)-피페라진-1-일메틸]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-{[2-(2-벤질옥시-5-클로로-페닐)-에틸아미노]-메틸}-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-{3-[(2-모르폴린-4-일-에틸아미노)-메틸]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-{3-[(3-모르폴린-4-일-프로필아미노)-메틸]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(피리딘-2-카르보닐)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(2-메틸-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3,4-디플루오로-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-플루오로-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3,4-디클로로-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-메톡시-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-플루오로-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3,5-디클로로-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-메톡시-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-이미다졸-4-카르보닐]-벤조산 tert-부틸 에스테르;3-[5-아미노-4-(3,5-디플루오로-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(벤조[1,3]디옥솔-5-카르보닐)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-클로로-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3,4-디메톡시-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-벤질옥시-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-플루오로-3-메틸-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;{3-[5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-이미다졸-4-카르보닐]-페녹시}-아세트산 tert-부틸 에스테르;3-[5-아미노-4-(3-클로로-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-벤조일-2-메틸-이미다졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드:3-(5-아미노-4-벤조일-2-프로필-이미다졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-카르바모일메톡시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-(5-아미노-4-{3-[2-(4-메틸-피페라진-1-일)-2-옥소-에톡시]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(2-옥소-2-피페라진-1-일-에톡시)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-{3-[2-(3-아미노-피롤리딘-1-일)-2-옥소-에톡시]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-{3-[2-(3-메틸아미노-피롤리딘-1-일)-2-옥소-에톡시]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-{3-[2-(3,5-디메틸-피페라진-1-일)-2-옥소-에톡시]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(2-모르폴린-4-일-2-옥소-에톡시)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-{[(1H-벤조이미다졸-2-일메틸)-카르바모일]-메톡시}-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-{[2-(2-벤질옥시-5-클로로-페닐)-에틸카르바모일]-메톡시}-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-{[2-(5-클로로-2-히드록시-페닐)-에틸카르바모일]-메톡시}-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-피라진-2-일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(3-피리딘-2-일-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(피리딘-2-카르보닐)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-시클로펜탄카르보닐-피라졸-1-일)-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(벤조[1,3]디옥솔-5-카르보닐)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(2-플루오로-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-에톡시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-메톡시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-시클로프로폭시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-메톡시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3,4-디메톡시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-메틸술파닐-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-메틸술파닐-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-플루오로-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-플루오로-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3,4-디플루오로-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3,5-디플루오로-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-플루오로-3-메틸-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(4-플루오로-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-(5-아미노-4-시클로헥산카르보닐-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-비닐옥시-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-([1,3,4]옥사디아졸-2-일메톡시)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸벤즈아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (2-메틸-시클로헥실)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 페닐아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (1-에틸-프로필)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 비시클로[2.2.1]헵트-2-일아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (1-에티닐-시클로헥실)아미드;3-[5-아미노-4-(2,5-디메틸-피롤리딘-1-카르보닐)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 4-메톡시-벤질아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 인단-1-일아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 벤질아미드;3-[5-아미노-4-(피페리딘-1-카르보닐)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 시클로헥실아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 시클로프로필아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 3-클로로벤질아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 시클로펜틸아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 2,4-디클로로-벤질아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 시클로헥실메틸-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 3,4-디클로로-벤질아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (4-메틸-시클로헥실)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 3-트리플루오로메틸-벤질아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (4-tert-부틸-시클로헥실)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (2,2-디메틸-프로필)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 3-메톡시-벤질아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 4-플루오로-벤질아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (1-에틸-피롤리딘-2-일메틸)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 2-메틸-벤질아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (피리딘-2-일메틸)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (2-모르폴린-4-일-에틸)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (1-시클로헥실-에틸)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (1-페닐-에틸)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (2,2-디메틸-프로필)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (1-에틸-피롤리딘-2-일메틸)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 (2-피롤리딘-1-일-에틸)-아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸-페닐)-1H-피라졸-4-카르복실산 시클로헥실-메틸-아미드;3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(3-피라진-2-일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸벤즈아미드;3-[5-아미노-4-(3-피리미딘-5-일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-피리미딘-5-일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-피리미딘-2-일-벤조일)-이미다졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;5-아미노-1-(5-시클로프로필카르바모일-2-메틸페닐)-4-메틸술포닐벤조일-1H-이미다졸;5-아미노-1-(5-시클로프로필카르바모일-2-메틸페닐)-4-[3-(5-메틸)옥사디아졸-3-일벤조일]-1H-이미다졸;3-(5-아미노-4-{3-[2-(4-메틸-피페라진-1-일)-에톡시]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-[5-아미노-4-(3-{2-[비스-(2-히드록시-에틸)-아미노]-에톡시}-벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(2-디메틸아미노-에톡시)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(2,3-디히드록시-프로폭시)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸벤즈아미드;3-(5-아미노-4-{3-[2-(4-클로로-페녹시)-에톡시]-벤조일}-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(4H-[1,2,4]트리아졸-3-일)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;3-{5-아미노-4-[3-(4H-[1,2,4]트리아졸-3-일)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드; 및3-{5-아미노-4-[3-(4H-[1,2,4]트리아졸-3-일)-벤조일]-피라졸-1-일}-N-시클로프로필-4-메틸-벤즈아미드;또는 그의 제약학상 허용되는 염으로 이루어진 군에서 선택되는 화합물.
- 제1항에 있어서, 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-N-시클로프로필-4-메틸벤즈아미드 또는 그의 제약학상 허용되는 염인 화합물.
- 제1항에 있어서, 3-(5-아미노-4-벤조일-피라졸-1-일)-N-시클로프로필-4-메틸-벤즈아미드인 화합물.
- 제22항에 있어서, 제약학상 허용되는 염 형태인 화합물.
- 제24항에 있어서, 제약학상 허용되는 염 형태인 화합물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48342803P | 2003-06-26 | 2003-06-26 | |
US60/483,428 | 2003-06-26 | ||
US49905403P | 2003-08-29 | 2003-08-29 | |
US60/499,054 | 2003-08-29 | ||
US56048104P | 2004-04-07 | 2004-04-07 | |
US60/560,481 | 2004-04-07 | ||
PCT/US2004/020384 WO2005009973A1 (en) | 2003-06-26 | 2004-06-24 | 5-membered heterocycle-based p38 kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060024813A KR20060024813A (ko) | 2006-03-17 |
KR101120857B1 true KR101120857B1 (ko) | 2012-04-12 |
Family
ID=34108816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057024679A KR101120857B1 (ko) | 2003-06-26 | 2004-06-24 | 5원의 헤테로사이클-기재 p38 키나제 억제제 |
Country Status (27)
Country | Link |
---|---|
US (4) | US7863314B2 (ko) |
EP (2) | EP2298743B1 (ko) |
JP (1) | JP4838121B2 (ko) |
KR (1) | KR101120857B1 (ko) |
CN (1) | CN1832928B (ko) |
AT (1) | ATE517872T1 (ko) |
AU (1) | AU2004259662B2 (ko) |
BR (1) | BRPI0411825B8 (ko) |
CA (1) | CA2526455C (ko) |
CY (2) | CY1111985T1 (ko) |
DK (2) | DK2298743T3 (ko) |
EC (2) | ECSP056206A (ko) |
ES (1) | ES2393950T3 (ko) |
HK (2) | HK1088895A1 (ko) |
HR (2) | HRP20110757T1 (ko) |
IL (1) | IL172182A (ko) |
IS (2) | IS2916B (ko) |
MA (1) | MA27888A1 (ko) |
MX (1) | MXPA05013824A (ko) |
MY (1) | MY158162A (ko) |
NO (1) | NO334947B1 (ko) |
NZ (1) | NZ544230A (ko) |
PL (2) | PL1641764T3 (ko) |
PT (2) | PT1641764E (ko) |
SI (2) | SI1641764T1 (ko) |
TW (2) | TWI452035B (ko) |
WO (1) | WO2005009973A1 (ko) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7485657B2 (en) | 2004-05-12 | 2009-02-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
CA2606226A1 (en) * | 2005-04-27 | 2006-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
DE102005031580A1 (de) * | 2005-07-06 | 2007-01-11 | Aicuris Gmbh & Co. Kg | Substituierte Sulfolanylpyrazole und ihre Verwendung |
GB0603684D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
KR20110007258A (ko) | 2006-03-22 | 2011-01-21 | 에프. 호프만-라 로슈 아게 | 11-베타-hsd-1로서의 피라졸 |
CA2648407A1 (en) * | 2006-04-03 | 2007-10-18 | Stowers Institute For Medical Research | Compositions and methods for treating polycystic kidney disease |
BRPI0717873A2 (pt) * | 2006-10-30 | 2013-10-29 | Novartis Ag | Derivado de 3-amino-pirazol-4-carboxamida úteis como inibidores de proteína quinases |
GB0621978D0 (en) * | 2006-11-03 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of p38 mitogen-activated protein kinase |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
WO2009011897A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Combinations for the treatment of b-cell proliferative disorders |
CA2694983A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
AU2008275891B2 (en) * | 2007-07-19 | 2013-10-10 | H.Lundbeck A/S | 5-membered heterocyclic amides and related compounds |
WO2009085797A1 (en) * | 2007-12-21 | 2009-07-09 | Gilead Sciences, Inc. | Processes for preparing hiv reverse transcriptase inhibitors |
DE102008015033A1 (de) * | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung |
US20090281150A1 (en) * | 2008-04-09 | 2009-11-12 | Nicola Frances Bateman | Compound 249 |
WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
JP5600104B2 (ja) | 2008-08-01 | 2014-10-01 | ベンティアールエックス ファーマシューティカルズ, インコーポレイテッド | Toll様受容体アゴニスト処方物およびその使用 |
ES2705101T3 (es) | 2008-11-06 | 2019-03-21 | Ventirx Pharmaceuticals Inc | Métodos de síntesis de derivados de benzazepinas |
BR112012008094A2 (pt) | 2009-08-07 | 2020-08-18 | Chugai Seiyaku Kabushiki Kaisha | derivado de aminopirazol, seu uso, composição farmacêutica que o compreende, agentes para inibir a atividade de fgfr e para prevenir ou tratar câncer |
EP2467380B1 (en) | 2009-08-18 | 2016-11-30 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
CN105669553A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
WO2011038261A1 (en) * | 2009-09-24 | 2011-03-31 | Selexagen Therapeutics, Inc. | Heterocyclic kinase inhibitors |
CA2789847A1 (en) | 2010-02-15 | 2011-08-18 | Synovo Gmbh | Kinase modulators for the treatment of cancer |
EP3061751A1 (en) * | 2010-09-21 | 2016-08-31 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
US8993631B2 (en) | 2010-11-16 | 2015-03-31 | Novartis Ag | Method of treating contrast-induced nephropathy |
EP2460519A1 (en) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
JP5620417B2 (ja) * | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
NZ628392A (en) * | 2012-03-20 | 2016-06-24 | Mereo Biopharma 1 Ltd | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
WO2015084936A1 (en) * | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
US9802920B2 (en) | 2013-12-13 | 2017-10-31 | Hoffman-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
CN105814035B (zh) | 2013-12-13 | 2018-02-02 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
US10479780B2 (en) | 2015-06-17 | 2019-11-19 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivatives |
US10214515B2 (en) * | 2015-08-20 | 2019-02-26 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Substituted pyrazoles as inhibitors of fibroblast growth factor receptor |
CA3016488C (en) | 2016-03-08 | 2023-04-11 | Mereo Biopharma 1 Limited | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
WO2017153701A1 (en) | 2016-03-08 | 2017-09-14 | Mereo Biopharma 1 Limited | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions |
GB201612240D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
GB201612238D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
WO2018059533A1 (zh) * | 2016-09-29 | 2018-04-05 | 南京明德新药研发股份有限公司 | p38αMAPK激酶抑制剂及其制备方法和应用 |
WO2018109667A1 (en) | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate white blood cells or neutrophils in a companion animal |
CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
HUE054266T2 (hu) | 2017-12-11 | 2021-08-30 | Mereo Biopharma 1 Ltd | 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében |
EP3585382B1 (en) | 2017-12-11 | 2021-07-14 | Mereo BioPharma 1 Limited | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
JP2021519334A (ja) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ, インコーポレイテッド | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 |
EP3563848A1 (en) * | 2018-04-30 | 2019-11-06 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Serpin inhibitors for the treatment of prion and prion-like diseases |
GB201815696D0 (en) * | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
GB201815699D0 (en) * | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
GB201815695D0 (en) * | 2018-09-26 | 2018-11-07 | Mereo Biopharma 1 Ltd | Synthetic method |
CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
CN113015730A (zh) * | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
CN112778333B (zh) * | 2021-01-23 | 2022-07-05 | 中国科学院新疆理化技术研究所 | 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1152421B (de) | 1961-03-21 | 1963-08-08 | Bayer Ag | Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3, 4-b]chinolinen |
JPS5111499Y2 (ko) | 1971-04-22 | 1976-03-27 | ||
USRE28819E (en) * | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
JPS5527916B2 (ko) | 1973-02-05 | 1980-07-24 | ||
JPS51112341A (en) | 1975-02-24 | 1976-10-04 | Konishiroku Photo Ind Co Ltd | Magenta dye image formation |
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
US6005109A (en) * | 1997-10-30 | 1999-12-21 | Pflizer Inc. | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
US6103900A (en) * | 1992-12-17 | 2000-08-15 | Pfizer Inc | Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity |
DE69323212T2 (de) | 1992-12-17 | 1999-05-27 | Pfizer | Pyrazole mit crf antagonistischer aktivität |
US5514643A (en) | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
US5646152A (en) | 1994-06-15 | 1997-07-08 | Pfizer Inc. | Methods of administering CRF antagonists |
CA2163399A1 (en) | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
DE19518054A1 (de) | 1995-03-08 | 1996-09-12 | Hoechst Schering Agrevo Gmbh | N-Arylpyrazolketone und deren Derivate, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
NZ327044A (en) | 1996-01-11 | 2000-01-28 | Smithkline Beecham Corp | Substituted imidazole compounds |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
WO1998028269A1 (en) | 1996-12-23 | 1998-07-02 | Du Pont Pharmaceuticals Company | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
WO1998052937A2 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
WO1999001452A1 (en) | 1997-07-02 | 1999-01-14 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
YU22400A (sh) | 1997-10-27 | 2003-08-29 | Agouron Pharmaceuticals Inc. | Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori |
US6376527B1 (en) | 1998-05-05 | 2002-04-23 | Syntex (U.S.A.) Llc | Pyrazole derivatives-p38 map kinase inhibitors |
US20020156114A1 (en) | 1998-05-05 | 2002-10-24 | Goldstein David Michael | Pyrazole derivatives - p38 MAP kinase inhibitors |
US6316466B1 (en) | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
NZ507558A (en) | 1998-05-05 | 2003-08-29 | F | Pyrazole derivatives as P-38 map kinase inhibitors |
US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
AU772477B2 (en) | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
WO2000025780A1 (en) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
BR0009721A (pt) | 1999-04-15 | 2002-02-13 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteìna cìclica |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
NZ512957A (en) | 1999-11-10 | 2005-01-28 | Ortho Mcneil Pharm Inc | Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a] pyrimidines and their use in inhibiting in vitro secretion of TNF-alpha and IL-1beta to treat neurodegenerative diseases |
AU2001230026A1 (en) | 2000-02-04 | 2001-08-14 | Novo-Nordisk A/S | 2,4-diaminothiazole derivatives |
AU9625501A (en) | 2000-09-21 | 2002-04-02 | Bristol Myers Squibb Co | Substituted azole derivatives as inhibitors of corticotropin releasing factor |
CA2429628A1 (en) | 2000-11-17 | 2002-05-23 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
AU2002219678A1 (en) | 2001-01-17 | 2002-07-30 | Boyean Kim | Sun visor having office work apparatus |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
MXPA03010269A (es) | 2001-05-11 | 2004-05-05 | Vertex Pharma | Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38. |
HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
PT1699800E (pt) * | 2003-12-23 | 2010-04-12 | Novartis Ag | Inibidores de quinase p-38 heterocíclicos bicíclicos |
JP2007084437A (ja) | 2003-12-26 | 2007-04-05 | Dai Ichi Seiyaku Co Ltd | アミノアルキルピラゾール誘導体 |
-
2004
- 2004-06-24 TW TW093118259A patent/TWI452035B/zh not_active IP Right Cessation
- 2004-06-24 DK DK10164367.4T patent/DK2298743T3/da active
- 2004-06-24 MX MXPA05013824A patent/MXPA05013824A/es active IP Right Grant
- 2004-06-24 PT PT04777075T patent/PT1641764E/pt unknown
- 2004-06-24 PL PL04777075T patent/PL1641764T3/pl unknown
- 2004-06-24 CN CN2004800180564A patent/CN1832928B/zh active Active
- 2004-06-24 PL PL10164367T patent/PL2298743T3/pl unknown
- 2004-06-24 SI SI200431766T patent/SI1641764T1/sl unknown
- 2004-06-24 WO PCT/US2004/020384 patent/WO2005009973A1/en active Application Filing
- 2004-06-24 DK DK04777075.5T patent/DK1641764T3/da active
- 2004-06-24 EP EP10164367A patent/EP2298743B1/en active Active
- 2004-06-24 AU AU2004259662A patent/AU2004259662B2/en active Active
- 2004-06-24 JP JP2006517650A patent/JP4838121B2/ja active Active
- 2004-06-24 BR BRPI0411825A patent/BRPI0411825B8/pt not_active IP Right Cessation
- 2004-06-24 KR KR1020057024679A patent/KR101120857B1/ko active IP Right Grant
- 2004-06-24 AT AT04777075T patent/ATE517872T1/de active
- 2004-06-24 NZ NZ544230A patent/NZ544230A/en unknown
- 2004-06-24 CA CA2526455A patent/CA2526455C/en active Active
- 2004-06-24 ES ES10164367T patent/ES2393950T3/es active Active
- 2004-06-24 SI SI200431950T patent/SI2298743T1/sl unknown
- 2004-06-24 PT PT101643674T patent/PT2298743E/pt unknown
- 2004-06-24 EP EP04777075A patent/EP1641764B1/en active Active
- 2004-06-24 TW TW100114024A patent/TWI449696B/zh not_active IP Right Cessation
- 2004-06-25 MY MYPI20042496A patent/MY158162A/en unknown
- 2004-06-25 US US10/877,534 patent/US7863314B2/en active Active
-
2005
- 2005-11-24 IL IL172182A patent/IL172182A/en active IP Right Grant
- 2005-12-08 EC EC2005006206A patent/ECSP056206A/es unknown
- 2005-12-21 MA MA28678A patent/MA27888A1/fr unknown
-
2006
- 2006-01-23 IS IS8255A patent/IS2916B/is unknown
- 2006-01-26 NO NO20060424A patent/NO334947B1/no unknown
- 2006-08-16 HK HK06109122.6A patent/HK1088895A1/xx unknown
- 2006-08-16 HK HK11107635.3A patent/HK1149764A1/xx not_active IP Right Cessation
-
2010
- 2010-11-19 US US12/950,649 patent/US8242117B2/en active Active
-
2011
- 2011-10-18 HR HR20110757T patent/HRP20110757T1/hr unknown
- 2011-10-27 CY CY20111101022T patent/CY1111985T1/el unknown
-
2012
- 2012-02-07 EC ECSP12006206 patent/ECSP12006206A/es unknown
- 2012-06-22 US US13/530,919 patent/US8410160B2/en active Active
- 2012-11-08 CY CY20121101064T patent/CY1113313T1/el unknown
- 2012-11-08 HR HRP20120900TT patent/HRP20120900T1/hr unknown
-
2013
- 2013-02-25 US US13/775,963 patent/US8580838B2/en active Active
-
2014
- 2014-01-28 IS IS9037A patent/IS2984B/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101120857B1 (ko) | 5원의 헤테로사이클-기재 p38 키나제 억제제 | |
JP4632544B2 (ja) | アミノピラゾール誘導体 | |
CA2376355C (en) | N-heterocyclic derivatives as nos inhibitors | |
JP4208925B2 (ja) | 治療薬 | |
JP2008525404A (ja) | 治療剤 | |
CZ20032676A3 (cs) | Pyrazolové deriváty pro léčení HIV | |
KR20110130388A (ko) | 제약 화합물 | |
KR20090116707A (ko) | 니코틴성 아세틸콜린 수용체 조절자 | |
KR20080039939A (ko) | 치료제로서의 피라졸 유도체 | |
KR20080032206A (ko) | Cb1 조절제로서의 피라졸 유도체 | |
RU2381219C2 (ru) | ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38 | |
JP2003176273A (ja) | アミド化合物およびその医薬としての用途 | |
ES2369541T3 (es) | Inhibidores de quinasa p38 basados en heterociclos de 5 miembros. | |
CZ20004818A3 (cs) | Deriváty kyseliny hydroxamové jako inhibitory produkce lidské CD23 a uvolňování TNF | |
WO2012029326A1 (ja) | 3-ピラゾリル-2-ピリドン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150120 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170119 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180118 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190116 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20200115 Year of fee payment: 9 |